Keywords: Vertex, Kalydeco, Cystic fibrosis, Misinterpretation of clinical data

Vertex slumps as firm revises Kalydeco data

Article | 30 May 2012

Print This

The USA’s Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares plunge 19% to $52.85 in early trading yesterday, after the company ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in